

Edgar Filing: AMERSHAM PLC - Form 425

AMERSHAM PLC
Form 425
January 23, 2004

Filed by General Electric Company
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14d-2
of the Securities Exchange Act of 1934

Subject Company: Amersham plc
Commission File No.: 1-14710

| | | | | |
|---------------------|---|---|---|----------|
| (GE logo) | o | o | o | |
| imagination at work | o | o | o | AMERSHAM |

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL ANY SECURITIES

21 JANUARY 2004

ACQUISITION OF AMERSHAM PLC

SATISFACTION OF PRE-CONDITIONS

RECOMMENDED SHARE EXCHANGE ACQUISITION OF AMERSHAM PLC ("AMERSHAM") BY GENERAL ELECTRIC COMPANY AND GE INVESTMENTS, INC. (TOGETHER "GE") BY MEANS OF A SCHEME OF ARRANGEMENT (THE "SCHEME") UNDER SECTION 425 OF THE COMPANIES ACT 1985 (THE "ACQUISITION")

On 10 October 2003, GE and Amersham announced the pre-conditional recommended Acquisition of Amersham applying a share exchange ratio which, at announcement, valued each Amersham share at 800 pence and the diluted share capital of Amersham at approximately (pound)5.7 billion (\$9.5 billion).

GE and Amersham today announce that the pre-conditions to the making of the Acquisition have now been satisfied. The pre-conditions included regulatory clearances from the European Commission, received today, and from the US anti-trust authorities, received on 1 December 2003.

It is expected that Amersham's preliminary results for 2003 will be announced and the documentation relating to the Scheme (which will incorporate Amersham's preliminary results) will be despatched to Amersham shareholders in approximately four weeks and it is intended that the Acquisition will complete in early April. Full details of the terms and conditions and expected timetable of the Acquisition and the Scheme will be set out in the scheme documentation.

Completion of the Acquisition remains subject to the satisfaction or, if permitted, waiver of the conditions to the Acquisition as set out in the press release of 10 October 2003, including, inter alia, the approval of Amersham shareholders and the sanction of the Scheme by the High Court.

Enquiries:

GE

Richard Wacker (GE Investor Relations)

+1 203 373 2468

Edgar Filing: AMERSHAM PLC - Form 425

| | |
|--------------------------------------|-----------------|
| Pam Wickham (GE Medical Systems) | +1 262 544 3530 |
| Louise Binns (GE Corporate Europe) | +32 2 235 6912 |
| Peter Stack (GE Corporate Financial) | +1 203 373 2283 |

GOLDMAN SACHS INTERNATIONAL

| | |
|-----------------|------------------|
| Richard Butland | +44 20 7774 1000 |
|-----------------|------------------|

AMERSHAM PLC

| | |
|---|------------------|
| Alexandra Morris (Investor Relations) | +44 1494 542 051 |
| Dr Lynne Gailey (Media Relations) | +44 1494 542 050 |
| Dr Graeme Holland (Media Relations) | +44 1494 542 115 |
| Nancy Thingstad (Media Relations, Norway) | +47 2318 5138 |
| Lucy Morrison (US Investor Relations) | +1 732 457 8092 |

J. P. MORGAN PLC

| | |
|--------------|------------------|
| Edward Banks | +44 20 7742 4000 |
|--------------|------------------|

MORGAN STANLEY & CO. LIMITED

| | |
|-------------------|------------------|
| Johannes Groeller | +44 20 7425 5000 |
|-------------------|------------------|

Goldman Sachs International, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for GE and no one else in connection with the Acquisition and will not be responsible to anyone other than GE for providing the protections afforded to customers of Goldman Sachs International nor for providing advice in relation to the Acquisition, or any matter referred to herein.

J. P. Morgan plc, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Amersham as joint financial adviser and no one else in connection with the Acquisition and will not be responsible to anyone other than Amersham for providing the protections afforded to customers of J. P. Morgan plc nor for providing advice in relation to the Acquisition, or any matter referred to herein.

Morgan Stanley & Co. Limited, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Amersham as joint financial adviser and for no one else in connection with the Acquisition and will not regard any other person as a client in relation to the Acquisition and will not be responsible to anyone other than Amersham for providing the protections afforded to clients of Morgan Stanley & Co Limited nor for providing advice in relation to the Acquisition, or any matter referred to herein.

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of GE resulting from and following the proposed acquisition of Amersham. These statements are based on management's current expectations and are inherently subject to uncertainties and changes in circumstances. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are factors relating to satisfaction of the pre-conditions and the conditions to the making and consummation of the proposed acquisition of Amersham, GE's ability to successfully combine the businesses of GE Medical Systems and Amersham and to

Edgar Filing: AMERSHAM PLC - Form 425

realize expected operating synergies from the proposed acquisition of Amersham, and changes in global, political, economic, business, competitive, market and regulatory forces. More detailed information about certain of these factors is contained in General Electric Company's and Amersham's filings with the SEC. Neither GE nor Amersham undertakes any obligation to update the forward-looking statements to reflect actual results, or any change in events, conditions, assumptions or other factors.

The foregoing does not constitute an offer for sale of any securities or an offer or an invitation to purchase any such securities. If and when GE commences the proposed acquisition of Amersham and the acquisition is implemented by way of a scheme of arrangement, any securities to be delivered pursuant to the scheme of arrangement will not be registered under the Securities Act but will be delivered in reliance on the exemption provided by Section 3(a)(10) thereof, and Amersham will furnish the acquisition document to the SEC under cover of a Form 6-K. If and when GE commences the proposed acquisition of Amersham and the acquisition is implemented by way of an offer rather than a scheme of arrangement, GE will file a registration statement relating to the offer with the SEC. If GE files a registration statement with the SEC, it will contain a prospectus and other documents relating to the offer. Such prospectus and other documents will contain important information about GE, Amersham, the offer and related matters. Holders of Amersham securities who are U.S. persons or who are located in the United States are urged to read such prospectus (if any) and other documents that would form part of such registration statement if and when it becomes available before they make any decision with respect to the offer. Holders of Amersham securities should also read the related solicitation/recommendation statement on Schedule 14D-9 that will be filed with the SEC by Amersham relating to the offer. Such prospectus and any other relevant documents filed by GE and Amersham with the SEC will be available free of charge at the SEC's web site at www.sec.gov and from GE. These documents will also be available for inspection and copying at the public reference room maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549, US. For further information about the public reference room, call the SEC at +1 800 732 0330.